argenx SE

OTCPK:ARGN.F Stock Report

Market Cap: US$50.8b

argenx Valuation

Is ARGN.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ARGN.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ARGN.F ($803.19) is trading below our estimate of future cash flow value ($2321.35)

Significantly Below Future Cash Flow Value: ARGN.F is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARGN.F?

Key metric: As ARGN.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ARGN.F. This is calculated by dividing ARGN.F's market cap by their current earnings.
What is ARGN.F's PE Ratio?
PE Ratio34.3x
EarningsUS$1.49b
Market CapUS$50.76b

Price to Earnings Ratio vs Peers

How does ARGN.F's PE Ratio compare to its peers?

The above table shows the PE ratio for ARGN.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.6x
ALNY Alnylam Pharmaceuticals
73.8x28.29%US$39.7b
ONC BeOne Medicines
67.2x29.05%US$34.5b
ASND Ascendis Pharma
26.6x16.93%US$15.3b
REGN Regeneron Pharmaceuticals
14.7x11.72%US$65.0b
ARGN.F argenx
34.3x21.68%US$43.6b

Price-To-Earnings vs Peers: ARGN.F is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the peer average (25.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does ARGN.F's PE Ratio compare vs other companies in the US Biotechs Industry?

13 CompaniesPrice / EarningsEstimated GrowthMarket Cap
RIGL Rigel Pharmaceuticals
1.5x-33.25%US$536.75m
ENLV Enlivex
0.1x-147.76%US$172.95m
AGEN Agenus
2x-48.42%US$129.18m
QTTB Q32 Bio
3x-25.09%US$98.35m
ARGN.F 34.3xIndustry Avg. 16.2xNo. of Companies13PE01632486480+
13 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ARGN.F is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the US Biotechs industry average (16.2x).

Price to Earnings Ratio vs Fair Ratio

What is ARGN.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARGN.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio34.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ARGN.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ARGN.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$982.68
0%
11.92%US$1,150.19US$696.38n/a15
May ’27US$724.55
US$991.43
+36.83%
11.99%US$1,163.28US$704.31n/a15
Apr ’27US$712.03
US$973.90
+36.78%
12.19%US$1,147.79US$694.93n/a15
Mar ’27n/a
US$992.33
0%
14.54%US$1,300.39US$662.02n/a15
Feb ’27US$842.00
US$975.90
+15.90%
12.63%US$1,175.14US$664.14n/a15
Jan ’27n/a
US$973.47
0%
12.61%US$1,168.22US$660.22n/a14
Dec ’26n/a
US$916.98
0%
13.02%US$1,147.91US$648.75n/a14
Nov ’26US$786.05
US$886.99
+12.84%
14.76%US$1,142.22US$553.31n/a14
Oct ’26n/a
US$849.11
0%
13.23%US$1,038.98US$563.51n/a14
Sep ’26US$683.14
US$833.40
+21.99%
13.03%US$1,035.21US$561.47n/a14
Aug ’26n/a
US$793.57
0%
10.15%US$933.30US$625.29n/a14
Jul ’26US$547.18
US$779.68
+42.49%
10.83%US$892.48US$618.96n/a15
Jun ’26n/a
US$753.65
0%
10.92%US$859.45US$596.05n/a15
May ’26n/a
US$771.24
0%
11.41%US$930.84US$612.24US$724.5515
Apr ’26n/a
US$749.41
0%
11.15%US$899.06US$584.23US$712.0314
Mar ’26n/a
US$661.57
0%
24.16%US$861.85US$160.76n/a14
Feb ’26US$697.42
US$655.07
-6.07%
24.48%US$876.28US$161.69US$842.0015
Jan ’26US$652.35
US$614.74
-5.77%
22.71%US$771.56US$161.61n/a15
Dec ’25n/a
US$598.33
0%
22.37%US$755.77US$162.47n/a15
Nov ’25n/a
US$581.77
0%
21.42%US$719.55US$167.97US$786.0515
Oct ’25n/a
US$566.47
0%
20.14%US$661.94US$171.86n/a15
Sep ’25n/a
US$560.48
0%
19.91%US$659.81US$171.31US$683.1415
Aug ’25US$466.88
US$527.07
+12.89%
21.22%US$684.35US$167.84n/a16
Jul ’25n/a
US$489.82
0%
22.11%US$677.31US$166.11US$547.1816
Jun ’25n/a
US$474.12
0%
22.79%US$686.43US$168.35n/a15
May ’25n/a
US$466.87
0%
22.57%US$676.37US$176.58n/a15
US$963.51
Fair Value
16.6% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/25 16:35
End of Day Share Price 2026/05/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 55 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Colleen KusyBaird
Joel BeattyBaird